A monthly headline price is a starting point for questions. It may refer to medicine alone, a particular presentation, an introductory offer, or a plan with separate service fees.
The most useful comparison is a written estimate for your actual prescription and a realistic period of care. These public prices were checked on September 23, 2026, and can change.
Compare the full recurring bill for the exact product, then ask what happens when the prescription or coverage changes.
Three public offers use three different structures
CoreAge Rx advertises compounded tirzepatide at $149 per month on its current offer page, describing all doses at the same price and no membership fee. Its public pharmacy information says the pharmacy is assigned after clinical review. See our CoreAge review for the unanswered order-specific questions.
Mochi lists a $79 one-month membership and compounded tirzepatide starting at $90 per month, with medication pricing dependent on dose. LillyDirect advertises Zepbound self-pay pricing starting at $299 for the 2.5 mg presentation; other strengths and program conditions affect the price. Those are different products and service arrangements, not interchangeable price tags.
Sources: CoreAge Rx: Current promotional offer · CoreAge Rx: Dispensing pharmacy FAQ · Mochi Health: Public care and pricing FAQs · LillyDirect: Zepbound self-pay options
Write down every part of the bill
Ask for the medicine price, visit or membership fee, any laboratory charge, shipping, supplies, and the billing interval. Confirm whether a quoted month means a specific number of doses and whether payment is required before the clinician determines eligibility.
For a subscription, note the renewal date and cancellation deadline. For a multi-month purchase, ask what happens if treatment changes or you cannot continue. A low average monthly figure can conceal a larger upfront commitment. Our provider shortlist organizes services by the questions their offers raise.
Sources: Mochi Health: Public care and pricing FAQs · Mochi Health: Terms · Mochi Health: Refunds · FDA: Managing medicine benefits and risks
Insurance is a separate calculation
An insurer may treat different products and diagnoses differently. Ask about the exact medicine, prior authorization, deductible, copayment, and renewal criteria. A provider offering authorization support cannot promise the insurer will approve a claim.
Do not assume a compounded prescription is covered because an approved brand is on a formulary. Ask your plan directly and keep its response. Our brand comparison explains why the indication and product name matter.
Sources: NIDDK: Prescription medicines for overweight and obesity · Mochi Health: Public care and pricing FAQs · Lilly: Zepbound prescribing information · Lilly: Mounjaro prescribing information
Affordability should include follow-up
A workable budget leaves room for care over time, including reassessment if side effects or changing health needs interrupt treatment. Ask who will discuss alternatives if the current plan becomes unaffordable.
Cost does not establish that a compounded prescription is appropriate. FDA says compounded GLP-1 drugs should be used only when a patient’s medical needs cannot be met by an approved drug. Read the compounding fieldnote, then use the notebook to bring the financial and clinical questions to one conversation.
Sources: FDA: Concerns with unapproved GLP-1 drugs · FDA: GLP-1 supply and compounding policy · NIDDK: Prescription medicines for overweight and obesity
The source shelf
- CoreAge Rx: Current promotional offer
Advertised terms only; no checkout, prescription or pharmacy product was tested.
- CoreAge Rx: Dispensing pharmacy FAQ
Provider description of pharmacy matching; actual dispensing pharmacy must be confirmed for an order.
- Mochi Health: Public care and pricing FAQs
Membership, medication and insurance pathways must be distinguished.
- LillyDirect: Zepbound self-pay options
Current prices vary by presentation and prescribed strength; higher-strength promotional pricing has refill timing conditions.
- Mochi Health: Terms
Platform payment and service terms; read with the selected treatment agreement.
- Mochi Health: Refunds
Cancellation and refund rules can differ for membership and a processed prescription.
- FDA: Managing medicine benefits and risks
General questions for clinical decision-making and medication follow-up.
- NIDDK: Prescription medicines for overweight and obesity
Chronic weight-management decisions and ongoing lifestyle care.
- Lilly: Zepbound prescribing information
Current approved-product label, revised August 2026; does not establish equivalence of compounded preparations.
- Lilly: Mounjaro prescribing information
Product-specific diabetes indications and safety information. Not an interchangeable label for compounded tirzepatide.
- FDA: Concerns with unapproved GLP-1 drugs
Compounding, fraudulent labels, dosing errors and the limits of adverse-event reports. Checked September 23, 2026.
- FDA: GLP-1 supply and compounding policy
Shortage resolution and restrictions on essentially copies; availability requires current professional assessment.
